Director, President, CEO and Secretary · LENZ Therapeutics, Inc. · Common Stock
Side
BUY
Value
$251K
Shares
28.1K
Price
$8.95
Executed
Mar 27, 2026
Disclosed
Mar 30, 2026
Disclosure timeline3 days from execution to publication · legal deadline 2 business days
Mar 27 executedMar 30, 2026 disclosed
LENZ · daily
Yahoo Finance chart API
◉This trade, on the day it was made▼Disclosure●Material company filing◯Other disclosed buy◯Other disclosed sellUnofficial public endpoint; daily OHLCV, split-adjusted. Replace with a licensed feed for production.
Disclosed 1 business day after execution (deadline: 2)
Historical behavior+8 / 15
First recorded trade by this actor in this security
Frequency & clustering+10 / 15
2 other actors traded the same direction within 14 days
Market events0 / 10
No material company filing within 60 days after the trade
The Insider Score measures how far a disclosure deviates from normal filing patterns. A high score is a prompt for research, not evidence of illegal insider trading.
Schimmelpennink Evert B. filed this Form 4 reporting a open-market purchase of LENZ on Mar 27, 2026. It became public on Mar 30, 2026. The filing establishes the reported transaction and the filer's stated role. It does not establish why the trade was made or what the filer knew.
Extraction
Method
Form 4 XML
Confidence
1.00
Director, President, CEO and Secretary
Schimmelpennink Evert B.cik:0001713795
Issuer
LENZ Therapeutics, Inc.cik:0001815776
Revision history · 0
No field has changed since this record was first ingested.
